Drug: KVD900
Phase 3Small molecule
Drug: KVD900 is one of 28 small molecule programs targeting Adolescent. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
27
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
32 competitors in Adolescent
#DrugCompanyPhaseTrials
1Zoloft
VViatris Specialty LLC
Approved
Fanapt
VVanda Pharmaceuticals
Approved
Abilify
OtsukaApproved
Sunlenca
GileadPhase 3
Prozac
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 3
Lithobid
SSolvay Pharmaceuticals
Phase 3
Camptosar
PfizerPhase 2
Brintellix
TakedaPhase 2
Cymbalta
Jazz PharmaceuticalsPhase 2
Valdoxan
NovartisPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Drug: KVD900. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- KKalVista Pharmaceuticals, Ltd.